@article{77aa3c9abb2c4001b457488b2e1cbc1d,
title = "Depression, antidepressants, and neurogenesis: A critical reappraisal",
abstract = "The neurogenesis hypothesis of depression posits (1) that neurogenesis in the subgranular zone of the dentate gyrus is regulated negatively by stressful experiences and positively by treatment with antidepressant drugs and (2) that alterations in the rate of neurogenesis play a fundamental role in the pathology and treatment of major depression. This hypothesis is supported by important experimental observations, but is challenged by equally compelling contradictory reports. This review summarizes the phenomenon of adult hippocampal neurogenesis, the initial and continued evidence leading to the development of the neurogenesis hypothesis of depression, and the recent studies that have disputed and/or qualified those findings, to conclude that it can be affected by stress and antidepressants under certain conditions, but that these effects do not appear in all cases of psychological stress, depression, and antidepressant treatment.",
keywords = "antidepressant, dentate gyrus, depression, neurogenesis, neurotrophic factors, stress",
author = "Hanson, {Nicola D.} and Owens, {Michael J.} and Nemeroff, {Charles B.}",
note = "Funding Information: Financial disclosure (preceding 12 months or anticipated in next 12 months): Nicola D Hanson, PhD Current employment: TRM Oncology. Michael J Owens, PhD Research Grants: NIH, Eli Lilly, Lundbeck A/S, Cybero-nics, Ortho-McNeil Janssen, AstraZeneca, Dainippon Sumitomo Pharma, SK Life Sciences, Sunovion Pharmaceuticals. Consultant: H Lundbeck A/S, RJ Reynolds. Patent: Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters (US 7 148 027 B2). Charles B Nemeroff, MD, PhD Research/Grants: National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ). Speakers Bureau: None. Consulting: Xhale, Takeda. Stockholder: CeNeRx BioPharma, NovaDel Pharma, PharmaNeuroBoost, Revaax Pharma, Xhale. Other Financial Interests: CeNeRx BioPharma, PharmaNeuroBoost. Patents: Method and devices for transdermal delivery of lithium (US 6 375 990B1), Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7 148 027B2). Scientific Advisory Boards: American Foundation for Suicide Prevention (AFSP), CeNeRx BioPharma, National Alliance for Research on Schizophrenia and Depression (NARSAD), NovaDel Pharma, PharmaNeuroBoost, Anxiety Disorders Association of America (ADAA). Board of Directors: AFSP, NovaDel Pharma.",
year = "2011",
month = dec,
doi = "10.1038/npp.2011.220",
language = "English (US)",
volume = "36",
pages = "2589--2602",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "13",
}